Literature DB >> 22993544

Soluble mesothelin-related protein in pleural effusion from patients with malignant pleural mesothelioma.

Nobukazu Fujimoto1, Kenichi Gemba, Michiko Asano, Sae Wada, Katsuichiro Ono, Shinji Ozaki, Takumi Kishimoto.   

Abstract

Malignant pleural mesothelioma (MPM) is a highly aggressive neoplasm primarily arising from surface serosal cells of the pleura and is strongly associated with asbestos exposure. Patients with MPM often develop pleural fluid as initial presentation. However, cytological diagnosis using pleural fluid is usually difficult and has limited utility. A useful molecular marker for differential diagnosis particularly with lung cancer (LC) is urgently needed. The aim of the present study was to investigate the diagnostic value of soluble mesothelin-related protein (SMRP) in pleural fluid. Pleural fluids were collected from 23 patients with MPM, 38 with LC, 26 with benign asbestos pleurisy (BAP), 5 with tuberculosis pleurisy (TP) and 4 with chronic heart failure (CHF), and the SMRP concentration was determined. All data were analyzed by using non-parametric two-sided statistical tests. The median concentration of SMRP in MPM, LC, BAP, TP and CHF were 11.5 (range 0.90-82.80), 5.20 (0.05-36.40), 6.65 (1.45-11.25), 3.20 (1.65-6.50) and 2.03 (1.35-2.80) nmol/l, respectively. The SMRP concentration was significantly higher in MPM than in the other diseases (P=0.001). The area under the ROC curve (AUC) values of the MPM diagnosis was 0.75 for the differential diagnosis from the other groups. Based on the cut-off value of 8 nmol/l, the sensitivity and specificity for diagnosis of MPM were 70.0 and 68.4%, respectively. These results indicate that the SMRP concentration in pleural fluid is a useful marker for the diagnosis of MPM.

Entities:  

Year:  2010        PMID: 22993544      PMCID: PMC3445880          DOI: 10.3892/etm_00000048

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  27 in total

1.  Diagnosis and initial management of nonmalignant diseases related to asbestos.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  2004-09-15       Impact factor: 21.405

2.  Expression of mesothelin mRNA in pure pancreatic juice from patients with pancreatic carcinoma, intraductal papillary mucinous neoplasm of the pancreas, and chronic pancreatitis.

Authors:  Hiroyuki Watanabe; Gensaku Okada; Koushiro Ohtsubo; Yasushi Yamaguchi; Hisatsugu Mouri; Yoshiharu Motoo; Tokio Wakabayashi; Norio Sawabu
Journal:  Pancreas       Date:  2005-05       Impact factor: 3.327

3.  Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses.

Authors:  A Bhattacharjee; W G Richards; J Staunton; C Li; S Monti; P Vasa; C Ladd; J Beheshti; R Bueno; M Gillette; M Loda; G Weber; E J Mark; E S Lander; W Wong; B E Johnson; T R Golub; D J Sugarbaker; M Meyerson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-13       Impact factor: 11.205

Review 4.  Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis.

Authors:  Q-L Liang; H-Z Shi; X-J Qin; X-D Liang; J Jiang; H-B Yang
Journal:  Thorax       Date:  2007-06-15       Impact factor: 9.139

5.  Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.

Authors:  Harvey I Pass; Anil Wali; Naimei Tang; Alla Ivanova; Sergey Ivanov; Michael Harbut; Michele Carbone; Jeffrey Allard
Journal:  Ann Thorac Surg       Date:  2008-01       Impact factor: 4.330

6.  Analysis of asbestos fibers in lung parenchyma, pleural plaques, and mesothelioma tissues of North American insulation workers.

Authors:  N Kohyama; Y Suzuki
Journal:  Ann N Y Acad Sci       Date:  1991-12-31       Impact factor: 5.691

7.  Diagnostic value of carcinoembryonic antigen in malignant pleural effusion: a meta-analysis.

Authors:  Huan-Zhong Shi; Qiu-Li Liang; Jing Jiang; Xue-Jun Qin; Hai-Bo Yang
Journal:  Respirology       Date:  2008-04-14       Impact factor: 6.424

8.  Mesothelin-family proteins and diagnosis of mesothelioma.

Authors:  Bruce W S Robinson; Jenette Creaney; Richard Lake; Anna Nowak; A William Musk; Nick de Klerk; Pernilla Winzell; Karl Erik Hellstrom; Ingegerd Hellstrom
Journal:  Lancet       Date:  2003-11-15       Impact factor: 79.321

9.  Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers.

Authors:  K Chang; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

10.  Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer.

Authors:  Joachim Schneider; Hans Hoffmann; Hendrik Dienemann; Felix J F Herth; Michael Meister; Thomas Muley
Journal:  J Thorac Oncol       Date:  2008-11       Impact factor: 15.609

View more
  8 in total

1.  Aberrant DNA methylation profile in pleural fluid for differential diagnosis of malignant pleural mesothelioma.

Authors:  Masanori Fujii; Nobukazu Fujimoto; Akio Hiraki; Kenichi Gemba; Keisuke Aoe; Shigeki Umemura; Hideki Katayama; Nagio Takigawa; Katsuyuki Kiura; Mitsune Tanimoto; Takumi Kishimoto
Journal:  Cancer Sci       Date:  2012-01-13       Impact factor: 6.716

2.  Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA.

Authors:  Rosa Filiberti; Stefano Parodi; Roberta Libener; Giovanni Paolo Ivaldi; Pier Aldo Canessa; Donatella Ugolini; Barbara Bobbio; Paola Marroni
Journal:  Med Oncol       Date:  2013-03-27       Impact factor: 3.064

3.  Clinical Investigation of Benign Asbestos Pleural Effusion.

Authors:  Nobukazu Fujimoto; Kenichi Gemba; Keisuke Aoe; Katsuya Kato; Takako Yokoyama; Ikuji Usami; Kazuo Onishi; Keiichi Mizuhashi; Toshikazu Yusa; Takumi Kishimoto
Journal:  Pulm Med       Date:  2015-11-24

4.  Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis.

Authors:  Ai Cui; Xiao-Guang Jin; Kan Zhai; Zhao-Hui Tong; Huan-Zhong Shi
Journal:  BMJ Open       Date:  2014-02-24       Impact factor: 2.692

5.  Clinical significance of soluble CD26 in malignant pleural mesothelioma.

Authors:  Nobukazu Fujimoto; Kei Ohnuma; Keisuke Aoe; Osamu Hosono; Taketo Yamada; Takumi Kishimoto; Chikao Morimoto
Journal:  PLoS One       Date:  2014-12-19       Impact factor: 3.240

6.  Diagnostic value of soluble mesothelin-related peptides in pleural effusion for malignant pleural mesothelioma: An updated meta-analysis.

Authors:  Ruiyue Gao; Feng Wang; Zhen Wang; Yanbing Wu; Lili Xu; Yue Qin; Huanzhong Shi; Zhaohui Tong
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

7.  Significance of secretory leukocyte peptidase inhibitor in pleural fluid for the diagnosis of benign asbestos pleural effusion.

Authors:  Takumi Kishimoto; Yoko Kojima; Nobukazu Fujimoto
Journal:  Sci Rep       Date:  2021-06-21       Impact factor: 4.379

8.  Pleural effusion biomarkers and computed tomography findings in diagnosing malignant pleural mesothelioma: A retrospective study in a single center.

Authors:  Takehiro Otoshi; Yuki Kataoka; Shunkichi Ikegaki; Emiko Saito; Hirotaka Matsumoto; Sawako Kaku; Masatoshi Shimada; Masataka Hirabayashi
Journal:  PLoS One       Date:  2017-10-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.